Open terminalDashboard

Last updated Nov 20, 7:54 AM ET · 1 update

Merck drug extended patient survival in stomach and esophageal cancer trial, Reuters reports

Reuters reported at 7:39 AM ET on Nov. 20 that a Merck drug helped patients with advanced stomach and esophageal cancers live longer in a trial.

More on this company

  1. Reuters reported at 7:39 AM ET on Friday, November 20, 2026, that a Merck drug lengthened survival for patients with advanced stomach and esophageal cancers in a clinical trial.

What happened

Reuters reported at 7:39 AM ET on Friday, November 20, 2026, that a Merck medicine extended how long patients lived in a trial of advanced cancers of the stomach and the esophagus (the food pipe). The Reuters item as available to us carries only its headline, so we have no further detail on the drug, the size of the benefit or the trial design. Merck's own statement on the result is not among the reports we have.

How the stock has moved

Merck (MRK) traded at $133.40 in pre-market trading, before the regular session opens, up 0.50% from Thursday's close of $132.74. That is the move since the Reuters report appeared and from the prior close.

Merck & Co. (MRK) since the news
MeasureValue
Price, pre-market trading$133.40
Since the close before the first report (Thursday, November 19, 2026)+0.50%
Change from the close on Thursday, November 19, 2026+0.50%
Market value at the close on Thursday, November 19, 2026$327.24 billion

Source: Stock quote; the close before the first report from our saved closes · as of November 20, 2026 at 7:54 AM ET · Shows what the stock did after the news was first reported, not why.

Its suppliers and customers

Company filings name three suppliers of Merck: Verona Pharma, Sidera Therapeutics and Doctor Fultz Pharma. None is listed on an exchange, so none has a share price, and none has traded since its last close. No customers are on file.

Suppliers and customers of Merck, and how they are trading
CompanyRoleStockSince last close
Verona PharmaSupplierNot listed—
Sidera TherapeuticsSupplierNot listed—
Doctor Fultz PharmaSupplierNot listed—

Source: Relationships named in company filings (Earnings call transcript); stock quotes · as of November 20, 2026 at 7:54 AM ET · A supplier or customer moving the same day is not evidence that one move caused the other.

Sources

  • — Reuters

How this was made

Written from WiseView data and the sources credited above, and checked before it went up. It is updated as new reports come in, and every update is checked before it goes up. How this report is made

For information only, not investment advice.

More from the desk

Follow MRK in the terminal.

Every panel, HootAI, the squawk and the pre-market board, on one membership.

Annual

$83/mo

Billed annually, $997 once a year.

Monthly

$127/mo

Billed monthly. Cancel any time.

14-day free trial · no card needed · nothing to cancel. Buying for a team? Seats on one invoice.